MiNK Therapeutics, Inc. (INKT)
INKT moved a median of -0.01% 30 minutes after news, and -0.52% by the close. How INKT actually reacts to news — the realized, point-in-time move the market made, measured across 214 labeled events over the last three years with zero look-ahead.
INKT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 28% | 183 |
| 30-min | -0.01% | 38% | 194 |
| 60-min | -0.53% | 44% | 205 |
| to close | -0.52% | 43% | 214 |
| Middle 50% of INKT reactions | -1.98% to +0.79% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 214 |
Half of all MiNK Therapeutics, Inc. news events land between -1.98% and +0.79% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How INKT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | 0.00% | 46% | -2.26% |
| Analyst downgrades | 12 | +0.99% | 67% | -3.33% |
| Rating reiterations | 19 | -0.41% | 37% | -1.62% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how INKT ranks against every other measured name →
That’s how INKT usually reacts — get an email when it moves on news →Email me when INKT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INKT's baseline. Nothing else.
Recent INKT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 | Press release | GlobeNewswire | -0.47% | -2.51% | |
| MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy | Press release | GlobeNewswire | -0.72% | -0.56% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.53% | |
| Form 8-K MiNK Therapeutics, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.57% | |
| Form S-8 MiNK Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +1.53% | |
| MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury | Press release | GlobeNewswire | +0.00% | -2.57% | |
| MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium | Press release | GlobeNewswire | — | -8.10% | |
| MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates | Press release | GlobeNewswire | +0.00% | -5.98% | |
| Form 8-K MiNK Therapeutics, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | — | +0.20% | |
| MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting | Press release | GlobeNewswire | +0.00% | +2.25% | |
| MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness | Press release | GlobeNewswire | +5.64% | +15.64% | |
| MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications | Press release | GlobeNewswire | +2.59% | +2.98% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -3.65% | |
| Form 8-K MiNK Therapeutics, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -3.34% | |
| MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation | Press release | GlobeNewswire | -1.44% | -3.34% | |
| MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness | Press release | GlobeNewswire | +0.00% | -5.66% | |
| MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 | Press release | GlobeNewswire | +0.09% | +1.51% | |
| MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs | Press release | GlobeNewswire | +0.00% | -0.55% | |
| Form ARS MiNK Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -2.52% | |
| Form DEF 14A MiNK Therapeutics, Inc. For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -2.52% | |
| MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer | Press release | GlobeNewswire | +1.33% | -0.77% | |
| MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 | Press release | GlobeNewswire | +2.14% | +6.22% | |
| MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy | Press release | GlobeNewswire | +0.00% | +2.10% | |
| MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference | Press release | GlobeNewswire | -10.09% | -10.20% | |
| Form 10-K MiNK Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -10.09% | -10.20% | |
| Form 8-K MiNK Therapeutics, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -4.92% | -0.47% | |
| MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum | Press release | GlobeNewswire | -4.92% | -0.47% | |
| Form 8-K MiNK Therapeutics, Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | +2.89% | |
| Form 8-K MiNK Therapeutics, Inc. For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | -0.95% | |
| MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs | Press release | GlobeNewswire | +4.18% | +5.17% | |
| C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology | Press release | Business Wire | -2.92% | -14.00% | |
| MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers | Press release | GlobeNewswire | -2.92% | -14.00% | |
| MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia | Press release | GlobeNewswire | +1.07% | +2.64% | |
| MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | Press release | GlobeNewswire | +0.37% | +0.36% | |
| Form 8-K MiNK Therapeutics, Inc. For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | +9.84% | |
| Form EFFECT MiNK Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -2.13% | |
| Form S-3/A MiNK Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -1.80% | |
| Form 8-K MiNK Therapeutics, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.00% | |
| MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors | Press release | GlobeNewswire | +0.53% | -3.63% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.05% | -6.98% | |
| MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | Press release | GlobeNewswire | -2.65% | -1.92% | |
| Form S-3 MiNK Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.59% | +2.04% | |
| MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025 | Press release | GlobeNewswire | +0.00% | -3.08% | |
| MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | Press release | GlobeNewswire | -1.39% | +1.00% | |
| MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting | Press release | GlobeNewswire | +0.00% | -2.53% | |
| Form 8-K MiNK Therapeutics, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -3.04% | |
| MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | Press release | GlobeNewswire | +0.14% | -3.04% | |
| MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | Press release | GlobeNewswire | -2.44% | -7.42% | |
| MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | Press release | GlobeNewswire | +0.00% | +6.52% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.09% | -14.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INKT section they belong to.
Where else INKT is measured.
INKT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MiNK Therapeutics, Inc.'s median reaction calculated?
Every labeled INKT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 214 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of INKT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INKT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.